Targeting MicroRNAs in Prostate Cancer Radiotherapy
- PMID: 28900507
- PMCID: PMC5595129
- DOI: 10.7150/thno.19934
Targeting MicroRNAs in Prostate Cancer Radiotherapy
Abstract
Radiotherapy is one of the most important treatment options for localized early-stage or advanced-stage prostate cancer (CaP). Radioresistance (relapse after radiotherapy) is a major challenge for the current radiotherapy. There is great interest in investigating mechanisms of radioresistance and developing novel treatment strategies to overcome radioresistance. MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression at the post-transcriptional level, participating in numerous physiological and pathological processes including cancer invasion, progression, metastasis and therapeutic resistance. Emerging evidence indicates that miRNAs play a critical role in the modulation of key cellular pathways that mediate response to radiation, influencing the radiosensitivity of the cancer cells through interplaying with other biological processes such as cell cycle checkpoints, apoptosis, autophagy, epithelial-mesenchymal transition and cancer stem cells. Here, we summarize several important miRNAs in CaP radiation response and then discuss the regulation of the major signalling pathways and biological processes by miRNAs in CaP radiotherapy. Finally, we emphasize on microRNAs as potential predictive biomarkers and/or therapeutic targets to improve CaP radiosensitivity.
Keywords: MicroRNAs; Prostate cancer; Radioresistance; Radiotherapy; Signalling pathway..
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures


Similar articles
-
microRNA-16-5p enhances radiosensitivity through modulating Cyclin D1/E1-pRb-E2F1 pathway in prostate cancer cells.J Cell Physiol. 2019 Aug;234(8):13182-13190. doi: 10.1002/jcp.27989. Epub 2018 Dec 10. J Cell Physiol. 2019. PMID: 30536619
-
Role of MicroRNAs in Treatment Response in Prostate Cancer.Curr Cancer Drug Targets. 2018;18(10):929-944. doi: 10.2174/1568009618666180315160125. Curr Cancer Drug Targets. 2018. PMID: 29644941 Free PMC article. Review.
-
Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.Adv Exp Med Biol. 2016;937:207-28. doi: 10.1007/978-3-319-42059-2_11. Adv Exp Med Biol. 2016. PMID: 27573902 Review.
-
MicroRNA-145 Modulates Tumor Sensitivity to Radiation in Prostate Cancer.Radiat Res. 2015 Dec;184(6):630-8. doi: 10.1667/RR14185.1. Epub 2015 Dec 3. Radiat Res. 2015. PMID: 26632856 Clinical Trial.
-
Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach.Sci Rep. 2017 Feb 22;7:41834. doi: 10.1038/srep41834. Sci Rep. 2017. PMID: 28225015 Free PMC article.
Cited by
-
The emerging role of exosomes in radiotherapy.Cell Commun Signal. 2022 Oct 31;20(1):171. doi: 10.1186/s12964-022-00986-1. Cell Commun Signal. 2022. PMID: 36316715 Free PMC article. Review.
-
MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome.Cancer Cell Int. 2024 Jul 4;24(1):233. doi: 10.1186/s12935-024-03420-3. Cancer Cell Int. 2024. PMID: 38965615 Free PMC article. Review.
-
Deregulated MicroRNA Signature Following Glioblastoma Irradiation.Cancer Control. 2019 Jan-Dec;26(1):1073274819847226. doi: 10.1177/1073274819847226. Cancer Control. 2019. PMID: 31046428 Free PMC article. Review.
-
Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators.Sci Rep. 2018 Jun 22;8(1):9540. doi: 10.1038/s41598-018-27831-1. Sci Rep. 2018. PMID: 29934570 Free PMC article.
-
Epigenetic repression of miR-17 contributed to di(2-ethylhexyl) phthalate-triggered insulin resistance by targeting Keap1-Nrf2/miR-200a axis in skeletal muscle.Theranostics. 2020 Jul 23;10(20):9230-9248. doi: 10.7150/thno.45253. eCollection 2020. Theranostics. 2020. PMID: 32802189 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
-
- Li L, Story M, Legerski RJ. Cellular responses to ionizing radiation damage. Int J Radiat Oncol Biol Phys. 2001;49:1157–62. - PubMed
-
- Soffen EM, Hanks GE, Hunt MA, Epstein BE. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. Int J Radiat Oncol Biol Phys. 1992;24:485–8. - PubMed
-
- Ling CC, Burman C, Chui CS, Kutcher GJ, Leibel SA, LoSasso T. et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys. 1996;35:721–30. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous